ClinicalTrials.gg
CompletedNCT01484496BLISS-SCUpdated Jun 6, 2018Results posted

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 3 interventional study of Placebo and Belimumab 200 mg SC in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 207 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
839
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
3rd of 36
839 · median 81
Started
2011
with 2 others
Phase 3
11 of 36
none open now
Registered
11th of 36
by date
Lead sponsor
7 of 36
Human Genome Sciences Inc., a GSK Company

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 11 in phase 3, and was the 11th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).

Read the detailed description

This is a Phase 3, multi-center, international, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) (200 mg weekly) in adult subjects with active Systemic Lupus Erythematosus (SLE). Approximately 816 SLE subjects will be randomized, with a target of about 544 subjects receiving belimumab and 272 subjects receiving placebo. Subjects completing the 52-week double-blind period can enter a 6-month open-label extension in which all subjects receive belimumab 200 mg SC weekly.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Subcutaneous
  • Lupus
  • Systemic Lupus Erythematosus
  • SLE
  • Belimumab
  • Autoimmune Disease
  • Antibodies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age.
  2. Clinical diagnosis of Systemic Lupus Erythematosus (SLE) by ACR criteria.
  3. Active SLE disease.
  4. Autoantibody-positive.
  5. On stable SLE treatment regimen which may include (for example, prednisone), antimalarial (for example, hydroxychloroquine) and/or (for example, azathioprine, methotrexate, mycophenolate, etc.)

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing.
  2. Have received treatment with any B cell targeted therapy (for example, rituximab or belimumab).
  3. Have received treatment an biological agent in the past year.
  4. Have received intravenous (IV) cyclophosphamide within 90 days of Day 0.
  5. Have severe active lupus kidney disease.
  6. Have severe active central nervous system (CNS) lupus.
  7. Have required management of acute or chronic infections within the past 60 days.
  8. Have current drug or alcohol abuse or dependence.
  9. Have a positive test for (HIV), , or .
  10. Have a history of reactions to contrast agents or biological medicines.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
839 participants (actual)

Study arms

  • Placebo comparator
    Placebo plus standard therapy

    Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.

    Biological: Placebo · Drug: Standard therapy

  • Experimental
    Belimumab 200 mg SC plus standard therapy

    Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.

    Biological: Belimumab 200 mg SC · Drug: Standard therapy

Interventions

  • BiologicalPlacebo

    Placebo

  • Belimumab 200 mg SC

    Also known as: BENLYSTA™

  • DrugStandard therapy

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.

06

What researchers measure

Primary outcomes

  1. Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52

    SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).

    Time frame: Week 52

Secondary outcomes

  1. Time to First Severe Flare (as Measured by the Modified SLE Flare Index)

    Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SELENA SLEDAI SLE flare index that excludes severe flares that were triggered only by an increase in SELENA SLEDAI score to \>12 (since this may only represent a modest increase in disease activity). Only post-baseline severe flares were considered.

    Time frame: Baseline (Day 0, prior to dosing) to Week 52

  2. Percentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline

    For the analysis of steroid use, all steroid dosages were converted to a prednisone equivalent in mg. The average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, SC, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. At Baseline, the average daily prednisone dose was the sum of all prednisone doses over 7 consecutive days up to, but not including Day 0, divided by 7. For this analysis, the average prednisone dose was the total prednisone dose during weeks 40 through 52 divided by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline prednisone dose, Baseline SELENA SLEDAI score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).

    Time frame: Baseline (Day 0, prior to dosing), Weeks 40 through Week 52

07

Results

Posted Jul 25, 2017

Participant flow

Participants (Par.) with active systemic lupus erythematosus (SLE) and who were on appropriate stable standard SLE therapy for a period of at least 30 days prior to Day 0 before entering the study were eligible for participation in the study.

Period 1
Participant flow — Period 1
MilestonePlacebo SCBelimumab 200 mg SCOpen-Label - Placebo SC to Belimumab 200 mg SCOpen-Label - Belimumab 200 SC to Belimumab 200 mg SC
Started28055600
Completed21446300
Not completed669300
Withdrew: Protocol violation3400
Withdrew: Physician decision5100
Withdrew: Lack of efficacy101500
Withdrew: Adverse event254000
Withdrew: Withdrawal by subject151200
Withdrew: Lost to follow-up2600
Withdrew: Positive pregnancy1600
Withdrew: Treatment failure3600
Withdrew: Lack of compliance2100
Withdrew: Unable to visit site0200
Period 2
Participant flow — Period 2
MilestonePlacebo SCBelimumab 200 mg SCOpen-Label - Placebo SC to Belimumab 200 mg SCOpen-Label - Belimumab 200 SC to Belimumab 200 mg SC
Started00206456
Completed00191434
Not completed001522
Withdrew: Lack of efficacy0013
Withdrew: Adverse event00513
Withdrew: Other0096

Outcome measures

PrimaryPercentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52

SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).

Time frame:
Week 52
Reported as:
Number · Percentage of par.
Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52
Percentage of par.Placebo SCBelimumab 200 mg SC
Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 5248.461.4
Statistical analysis
  • Placebo SC vs Belimumab 200 mg SC · Regression, Logistic · p = 0.0006 · Odds ratio (or): 1.68 · 95% CI 1.25 to 2.25
SecondaryTime to First Severe Flare (as Measured by the Modified SLE Flare Index)

Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SELENA SLEDAI SLE flare index that excludes severe flares that were triggered only by an increase in SELENA SLEDAI score to \>12 (since this may only represent a modest increase in disease activity). Only post-baseline severe flares were considered.

Time frame:
Baseline (Day 0, prior to dosing) to Week 52
Reported as:
Median · Days
Time to First Severe Flare (as Measured by the Modified SLE Flare Index)
DaysPlacebo SCBelimumab 200 mg SC
Time to First Severe Flare (as Measured by the Modified SLE Flare Index)118 (2 to 364)171 (5 to 358)
Statistical analysis
  • Placebo SC vs Belimumab 200 mg SC · Cox proportional hazards model · p = 0.0004 · Hazard ratio (hr): 0.51 · 95% CI 0.35 to 0.74
SecondaryPercentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline

For the analysis of steroid use, all steroid dosages were converted to a prednisone equivalent in mg. The average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, SC, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. At Baseline, the average daily prednisone dose was the sum of all prednisone doses over 7 consecutive days up to, but not including Day 0, divided by 7. For this analysis, the average prednisone dose was the total prednisone dose during weeks 40 through 52 divided by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline prednisone dose, Baseline SELENA SLEDAI score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).

Time frame:
Baseline (Day 0, prior to dosing), Weeks 40 through Week 52
Reported as:
Number · Percentage of par.
Percentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline
Percentage of par.Placebo SCBelimumab 200 mg SC
Percentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline11.918.2
Statistical analysis
  • Placebo SC vs Belimumab 200 mg SC · Regression, Logistic · p = 0.0732 · Odds ratio (or): 1.65 · 95% CI 0.95 to 2.84

Adverse events

Collected over Serious adverse events (SAEs) and non-SAEs were collected from start of study drug administration to 51 weeks of treatment period/Exit visit for those par. who withdrew during double-blind treatment, plus another 6 months for open-label treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo SC2/280 (0.7%)44/280 (15.7%)218/280 (77.9%)
Belimumab 200 mg SC3/556 (0.5%)60/556 (10.8%)403/556 (72.5%)
Open-Label - Placebo SC to Belimumab 200 mg SC0/206 (0%)14/206 (6.8%)42/206 (20.4%)
Open-Label - Belimumab 200 SC to Belimumab 200 mg SC0/456 (0%)25/456 (5.5%)78/456 (17.1%)
Most frequent serious events
Showing 10 of 156
Most frequent serious events
EventPlacebo SCBelimumab 200 mg SCOpen-Label - Placebo SC to Belimumab 200 mg SCOpen-Label - Belimumab 200 SC to Belimumab 200 mg SC
ThrombocytopeniaBlood and lymphatic system disorders3/2800/5560/2060/456
Herpes zosterInfections and infestations0/2801/5562/2060/456
Abdominal abscessInfections and infestations0/2800/5562/2060/456
PneumoniaInfections and infestations1/2804/5561/2061/456
Renal failure acuteRenal and urinary disorders0/2804/5560/2060/456
CellulitisInfections and infestations2/2803/5560/2061/456
Pneumonia bacterialInfections and infestations2/2803/5560/2060/456
Nephrotic syndromeRenal and urinary disorders2/2800/5561/2060/456
HeadacheNervous system disorders2/2800/5560/2060/456
DysphagiaGastrointestinal disorders2/2800/5560/2060/456
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo SCBelimumab 200 mg SCOpen-Label - Placebo SC to Belimumab 200 mg SCOpen-Label - Belimumab 200 SC to Belimumab 200 mg SC
HeadacheNervous system disorders25/28057/5564/20610/456
Viral upper respiratory tract infectionInfections and infestations24/28048/5569/20617/456
NasopharyngitisInfections and infestations22/28038/5569/2067/456
NauseaGastrointestinal disorders22/28038/5561/2065/456
Urinary tract infection bacterialInfections and infestations18/28041/5562/20614/456
InsomniaPsychiatric disorders20/28018/5560/2061/456
CoughRespiratory, thoracic and mediastinal disorders19/28022/5561/2068/456
ArthralgiaMusculoskeletal and connective tissue disorders11/28031/5566/20611/456
Upper respiratory tract infection bacterialInfections and infestations14/28030/5563/2069/456
Back painMusculoskeletal and connective tissue disorders15/28028/5564/2065/456

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo SCBelimumab 200 mg SCTotal
Mean39.6 ± 12.6138.1 ± 12.1038.6 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Placebo SCBelimumab 200 mg SCTotal
Female268521789
Male123547
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo SCBelimumab 200 mg SCTotal
White/Caucasian/European Heritage160326486
Middle East/North African Heritage61016
Central Asian Heritage022
East Asian Heritage152944
Japanese Heritage161329
South Asian Heritage022
Southeast Asian Heritage3273105
African American/African Heritage305686
American Indian or Alaska Native214364
Native Hawaiian or Other Pacific Islander022
08

Study locations

207 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Peoria, Arizona 85381, United States
  • GSK Investigational Site
    Tucson, Arizona 85712, United States
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    La Jolla, California 92037-0943, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    San Francisco, California 94118, United States
  • GSK Investigational Site
    San Jose, California 95126-1650, United States
  • GSK Investigational Site
    San Leandro, California 94578, United States
  • GSK Investigational Site
    Tustin, California 92780, United States
  • GSK Investigational Site
    Upland, California 91786, United States
  • GSK Investigational Site
    Bridgeport, Connecticut 06606, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Boca Raton, Florida 33432, United States
  • GSK Investigational Site
    Boca Raton, Florida 33486, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33334, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Orlando, Florida 32806-6264, United States
  • GSK Investigational Site
    Plantation, Florida 33324, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Atlanta, Georgia 30303, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Duluth, Georgia 30096, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30045, United States
  • GSK Investigational Site
    Marietta, Georgia 30060, United States
  • GSK Investigational Site
    Boise, Idaho 83704, United States
  • GSK Investigational Site
    Springfield, Illinois 62704, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Baltimore, Maryland 21205, United States
  • GSK Investigational Site
    Cumberland, Maryland 21502, United States
  • GSK Investigational Site
    Hagerstown, Maryland 21740, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Boston, Massachusetts 02118, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Saint Clair Shores, Michigan 48081, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Las Cruces, New Mexico 88011, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Lake Success, New York 11042, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Smithtown, New York 11787, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7280, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28210, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Cleveland, Ohio 44109, United States
  • GSK Investigational Site
    Columbus, Ohio 43203, United States
  • GSK Investigational Site
    Dayton, Ohio 45417, United States
  • GSK Investigational Site
    Toledo, Ohio 43614, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Bethlehem, Pennsylvania 18015, United States
  • GSK Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • GSK Investigational Site
    Wyomissing, Pennsylvania 19610, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Charleston, South Carolina 29425, United States
  • GSK Investigational Site
    Greenville, South Carolina 29601, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Jackson, Tennessee 38305, United States
  • GSK Investigational Site
    Memphis, Tennessee 38119, United States
  • GSK Investigational Site
    Allentown, Texas 75013, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Austin, Texas 78758, United States
  • GSK Investigational Site
    Dallas, Texas 75231, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77008, United States
  • GSK Investigational Site
    Houston, Texas 77034, United States
  • GSK Investigational Site
    Houston, Texas 77074, United States
  • GSK Investigational Site
    Nassau Bay, Texas 77058, United States
  • GSK Investigational Site
    Arlington, Virginia 22205-3606, United States
  • GSK Investigational Site
    Seattle, Washington 98133, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Pennsylvania, Wyoming 19610, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1181ACI, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1419AHN, Argentina
  • GSK Investigational Site
    La Plata, Buenos Aires B1902COS, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1426AAL, Argentina
  • GSK Investigational Site
    Vienna, A-1100, Austria
  • GSK Investigational Site
    Brussels, 1090, Belgium
  • GSK Investigational Site
    Bruxelles, 1200, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Cuiaba, Mato Grosso 78005-000, Brazil
  • GSK Investigational Site
    Juiz de Fora, Minas Gerais 36038-330, Brazil
  • GSK Investigational Site
    Curitiba, Paraná 80440-080, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • GSK Investigational Site
    Porto Alegre, Rio Grande Do Sul 90110-270, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21941-913, Brazil
  • GSK Investigational Site
    Salvador, 40050-410, Brazil
  • GSK Investigational Site
    São Paulo, 04032-060, Brazil
  • GSK Investigational Site
    Plovdiv, 4002, Bulgaria

Showing the first 100 of 207 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747. PubMed 34531304 ↗
  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗
  • Maslen T, Bruce IN, D'Cruz D, Ianosev M, Bass DL, Wilkinson C, Roth DA. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Sci Med. 2021 Feb;8(1):e000459. doi: 10.1136/lupus-2020-000459. PubMed 33568389 ↗
  • Lokhandwala T, Yue B, Coutinho AD, Bell CF. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus. Lupus Sci Med. 2021 Feb;8(1):e000438. doi: 10.1136/lupus-2020-000438. PubMed 33558436 ↗
  • Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018 Aug;27(9):1489-1498. doi: 10.1177/0961203318777634. Epub 2018 May 28. PubMed 29807477 ↗
  • Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2018 Aug;70(8):1256-1264. doi: 10.1002/art.40511. Epub 2018 Jun 15. PubMed 29671280 ↗
  • Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7. PubMed 28118533 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Feb 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 5 months after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2011
First posted
Dec 2, 2011
Start
Nov 16, 2011
Primary completionActual
Feb 13, 2015
CompletionActual
Oct 1, 2015
Results delay requested
Jun 11, 2015
Results first posted
Jul 25, 2017
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01484496
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 2, 2011
Start date
Nov 16, 2011
Primary completion
Feb 13, 2015
Completion
Oct 1, 2015
Results posted
Jul 25, 2017
Last update
Jun 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion